A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy

PHASE2TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

November 19, 2024

Study Completion Date

January 15, 2025

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

ATL1102 25mg

Dose and scheduled as specified in the Arm description

DRUG

ATL1102 50mg

Dose and scheduled as specified in the Arm description

DRUG

Placebo

Dose and scheduled as specified in the Arm description

Trial Locations (13)

1432

UMHAT Aleksandrovska Neurology clinic, Sofia

11000

University Children's Hospital, Belgrade

11070

Mother and Child Health Care Institute, Belgrade

Unknown

Royal Childrens Hospital, Melbourne

Queensland Children's Hospital, South Brisbane

The Children's Hospital at Westmead, Westmead

Eskisehir Osmangazi Universitesi Tip Fakultesi, Eskişehir

Yeditepe University Hospital, Istanbul

Marmara University Pendik Training and Research Hospital, Pendik

B9 5SS

Birmingham Heartlands Hospital, Birmingham

LS2 9NS

The General Infirmary at Leeds, Leeds Teaching Hospital NHS Trust, Leeds

WC1N 3JH

University College London (UCL) - Great Ormond Street Institute of Child Health (ICH), London

SY10 7AG

The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry

Sponsors
All Listed Sponsors
lead

Percheron Therapeutics

INDUSTRY

NCT05938023 - A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter